Drug Database
FI

fimasartan + rosuvastatin (Tubero / Tuvero)

✓ Approved

Boryung · AGTR1 · Small Molecule

What is fimasartan + rosuvastatin?

fimasartan + rosuvastatin is a small molecule developed by Boryung. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesTubero, Tuvero
CompanyBoryung
Drug ClassSmall Molecule
Molecular TargetAGTR1, HMGCR
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Boryung

Mechanism of Action

Molecular Targets

fimasartan + rosuvastatin acts on 2 molecular targets:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

fimasartan + rosuvastatin is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Vascular disordersHypertension✓ Approved
Metabolism and nutrition disordersHyperlipidaemiaPhase III

Related Research Articles

PubMedF&S science2026-07-24

Rosuvastatin mitigates ovarian ischemia-reperfusion injury in rats by modulating oxidative stress, inflammation, and angiogenesis.

Vahedi Nima N, Jafary Saleh S, Beheshti Rahim R

To investigate the protective effects of rosuvastatin against ovarian ischemia-reperfusion injury (I/R) in a rat model. Controlled experimental study using an induced ovarian torsion-detorsion model. Fifty adults female Wistar rats (aged 8-10 weeks, weighing 100-150 g). Intraperitoneal administration of rosuvastatin (5 mg/kg) 30 minutes before induction of ischemia in the designated treatment groups. Ovarian tissue levels of myeloperoxidase (MPO), malondialdehyde (MDA), total antioxidant capacity (TAC), and activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT); mRNA expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), tumor necrosis factor-α (TNF-α), and caspase-3; and semi-quantitative histopathological scoring of tissue damage. Ischemia and I/R significantly elevated MPO, MDA, VEGF, bFGF, TNF-α, and caspase-3 levels while worsening histological damage. Rosuvastatin pretreatment reduced MPO by 13%-16%, MDA by 9%, VEGF by 7%-14%, bFGF by 14%-37%, TNF-α by 34%-38%, and caspase-3 by 31%-39%; increased TAC by 20%; and markedly improved histopathological scores, including reduced follicular atresia. No significant changes were observed in SOD, GPx, or CAT activities. Rosuvastatin exerts protective effects against ovarian I/R by attenuating oxidative stress, inflammation, excessive angiogenesis, and apoptosis, independent of major antioxidant enzyme induction. These preclinical findings suggest potential adjunctive utility in limiting reperfusion injury after detorsion; however, protein-level validation, dose-response studies, post-ischemic administration, long-term fertility outcomes, and safety assessments are required before any clinical translation.

PMID 42492670
Read full article →
PubMedDrug metabolism and bioanalysis2026-07-23

Bioanalytical Method for Simultaneous Quantification of Itraconazole and Atorvastatin in Human Plasma.

Bodiwala Kunjan B KB, Pujara Flora J FJ, Khadela Avinash D AD, Savale Shrinivas S SS

Drug-drug interactions between statins and azole antifungal agents, due to the inhibition of the CYP3A4 enzyme by antifungals, increase the risk of adverse effects from statins. Thus, a precise bioanalytical method for quantifying Itraconazole and Atorvastatin in human plasma is essential. A liquid chromatographic method with protein precipitation and liquidliquid extraction was developed. Rosuvastatin calcium served as the internal standard. The method was validated per ICH M10 and USFDA guidelines and used to analyze spiked plasma samples. The method effectively separated Itraconazole, Atorvastatin, and the internal standard without plasma interference. It achieved linear responses for each drug in the 0.1-3.0 μg/mL range with regression coefficients > 0.99. The RSD for within-run and between-run responses was < 5%, and the average recovery exceeded 64%. The method accurately and precisely measured each analyte at the LLOQ level (0.1 μg/mL). A sensitive and selective bioanalytical HPLC method was developed, validated, and applied for the simultaneous estimation of Itraconazole and Atorvastatin in human plasma. This method ensures safe and effective co-administration of these medications in clinical practice, benefiting patient care.

PMID 42489331
Read full article →
PubMedFrontiers in pharmacology2026-07-23

Pharmacovigilance assessment of gout: a real-world study using the FAERS database.

Ren Honghao H, Yao Nannan N, Ren Xiaodong X, Su Yani Y et al.

Drug intervention is a key method for preventing gout, various drugs have been implicated as potential risk factors in individual studies. This study aims to comprehensively identify drugs linked to the development of gout. Data were obtained from the FDA Adverse Event Reporting System (FAERS), and disproportionality analysis was employed to quantitatively assess the associations between drugs and gout. Four complementary signal detection methods-Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS)-were utilized. To further delineate exposure-outcome relationships and identify influential predictors, least absolute shrinkage and selection operator (LASSO) logistic regression was implemented. Time-to-onset (TTO) analysis was conducted to examine the temporal dynamics between drug initiation and the occurrence of gout. Finally, a comprehensive assessment of the therapeutic indications of the drugs was performed. A total of 35 drugs were ultimately identified as potentially associated with the onset and progression of gout. Among these, several agents have been previously reported in the literature as having possible links to gout development. In addition, a number of novel candidates were detected for which evidence of an association with gout remains limited or has not been clearly established. These include Lenalidomide, Sacubitril valsartan, Ruxolitinib, Treprostinil, Octreotide, Selexipag, Rosuvastatin, Sitagliptin, Riociguat, Epoprostenol, Patiromer, Dasabuvir ombitasvir paritaprevir ritonavir, Tafamidis, Sparsentan, and Iloprost. Furthermore, TTO analysis suggested that approximately 75% of gout events occurred within 0.6 years following initiation of therapy. These pharmacotherapeutic agents are employed across diverse clinical settings, encompassing haematological malignancies, cardiovascular diseases, and pulmonary hypertension. These findings suggest the potential for targeted monitoring of drug-associated gout in clinical practice. When administering these medications, it may be crucial to regularly assess patients' uric acid levels and maintain heightened awareness for the possible onset of gout.

PMID 42488563
Read full article →
PubMedPhysiological research2026-07-22

The Effect of Rosuvastatin on Formalin-Induced Nociceptive Behavior in an Experimental Rat Model of Metabolic Syndrome.

García-Paz M M, López-Canales J J, Toledo-Blas M M, Franco-Vadillo A A et al.

The aim of this study was to determine the effect of rosuvastatin (10 mg/kg/day, p.o.) on the flinching nociceptive behavior produced by subcutaneous injection of 0.5 % formalin in the dorsum of the right hind paw from Wistar rats submitted to a 16-week treatment, including a standard rat chow diet (STD-diet) or a high fat-diet (HF-diet). At three days post-treatment, the formalin-induced nociceptive response was assessed for 1 h. Compared to the STD-diet, the HF-diet significantly increased the number of flinches in the second phase of the formalin test, as well as inducing higher body weight and levels of glucose, total cholesterol, triglycerides, insulin and blood pressure. Rosuvastatin significantly decreased the formalin-induced nociceptive behavior after both diets and significantly reduced those metabolic parameters in rats with a HF- but not STD-diet. Key words High-fat diet " Nociception " Metabolic syndrome " Formalin test.

PMID 42484081
Read full article →
PubMedSouth Dakota medicine : the journal of the South Dakota State Medical Association2026-07-19

Acute Lacunar Infarct in the Right Dorsal Pons Presenting as Internuclear Ophthalmoplegia Following Percutaneous Cardiac Intervention.

Roberts Angela A, Roberts Michael M, Amin Nessim N NN

A 58-year-old male with a history of type 1 diabetes, hypertension, smoking, and obesity, was seen by the inpatient neurology team for symptoms of dizziness and diplopia after cardiac catheterization. His symptoms caused him to feel nauseated and vomit and were improved with closing his right eye. It was noted that he was unable to adduct his right eye and had nystagmus of his left eye on exam. He had no ptosis, and convergence was preserved. The remaining physical exam was normal. Initial limited magnetic resonance imaging (MRI) was within normal limits; however, repeat limited brain MRI without contrast with brainstem cuts revealed punctate focus on restricted diffusion in the right dorsal pons compatible with a small acute infarct. He was started on dual antiplatelet therapy for 21 days followed by aspirin monotherapy daily, and rosuvastatin 40 mg daily. The patient was scheduled to follow up in the stroke clinic in 3 months and was also referred to ophthalmology, who recommended monitoring symptoms, which were gradually improving with an eye patch, indicating that he would likely slowly improve on his own.

PMID 42470333
Read full article →
PubMedHead & neck2026-07-18

Concurrent Statin Use and Overall Survival in Immune Checkpoint Inhibitor-Treated Mucosal Head and Neck Squamous Cell Carcinoma: A Multi-Institutional Real-World Analysis.

Khudaverdyan Allen A, Jabban Sophie S, Morales Emmanuel Garcia EG, Moses Lindsey L et al.

Preclinical evidence suggests statins enhance antitumor immunity. This study evaluates whether concurrent statin use during immune checkpoint inhibitor (ICI) therapy is associated with overall survival (OS) in mucosal head and neck squamous cell carcinoma (HNSCC). This retrospective study uses Epic COSMOS, a multi-health system electronic health record dataset. Adults with mucosal HNSCC receiving PD-1 inhibitors were included. Concurrent statin use required ≥ 2 statin orders from -365 to +180 days relative to ICI initiation. The primary outcome was OS from ICI initiation to death or last encounter. Among 21 456 patients, 5719 (26.7%) met concurrent statin criteria. In the fully adjusted model, statin use was associated with increased mortality (HR 1.08; 95% CI 1.04-1.13). In drug-specific analysis, rosuvastatin was associated with reduced mortality (HR 0.87; 0.80-0.96). Class-level statin use was not associated with improved survival, likely reflecting confounding by cardiovascular comorbidity. Rosuvastatin-specific findings warrant prospective investigation.

PMID 42469584
Read full article →

+5182 more articles available with a free account

Sign up free to view all articles →

Ask about fimasartan + rosuvastatin